| Literature DB >> 34725903 |
Jagannath Pal1, Yogita Rajput1, Shruti Shrivastava2,3, Renuka Gahine1,3, Varsha Mungutwar4, Tripti Barardiya5, Ankur Chandrakar4, Pinaka Pani Ramakrishna6, Sovna Shivani Mishra6, Hansa Banjara4, Vivek Choudhary7, Pradeep K Patra5, Masood A Shammas8.
Abstract
Oral squamous cell carcinoma (OSCC) is often preceded by a white patch on a surface of the mouth, called oral leukoplakia (OL). As accelerated telomere length (TL) shortening in dividing epithelial cells may lead to oncogenic transformation, telomere length measurement could serve as a predictive biomarker in OL. However, due to high variability and lack of a universal reference, there has been a limited translational application. Here, we describe an approach of evaluating TL using paired peripheral blood mononuclear cells (PBMC) as an internal reference and demonstrate its translational relevance. Oral brush biopsy and paired venous blood were collected from 50 male OL patients and 44 male healthy controls (HC). Relative TL was measured by quantitative PCR. TL of each OL or healthy sample was normalized to the paired PBMC sample (TL ratio). In OL patients, the mean TL ratio was significantly smaller not only in the patch but also in distal normal oral tissue, relative to healthy controls without a high-risk oral habit. Dysplasia was frequently associated with a subgroup that showed a normal TL ratio at the patch but significantly smaller TL ratio at a paired normal distal site. Our data suggest that evaluation of TL attrition using a paired PBMC sample eliminates the requirement of external reference DNA, makes data universally comparable and provides a useful marker to define high-risk OL groups for follow-up programs. Larger studies will further validate the approach and its broader application in other premalignant conditions.Entities:
Keywords: high-risk oral habits; oral cancer; oral leukoplakia; relative telomere length
Mesh:
Year: 2022 PMID: 34725903 PMCID: PMC9019888 DOI: 10.1002/1878-0261.13133
Source DB: PubMed Journal: Mol Oncol ISSN: 1574-7891 Impact factor: 7.449
Fig. 1Frequency and mean distribution of telomere length ratio in oral mucosa of healthy control and oral leukoplakia patients. (A) Comparison of frequency distribution of telomere length (TL) ratio of oral leukoplakia (OL) patients with healthy controls (HC). (I) Comparative distribution of all healthy controls (THC; n = 44), healthy controls without oral habit (NOHC; n = 25) and healthy controls with high‐risk oral habit (OHC; n = 19). (II) Comparative distribution of paired distal normal mucosa in OL patients (OLN; n = 50), oral patch in OL patients (OLP; n = 50) and THC (n = 44). (III) Comparative distribution of OLN (n = 50), oral patch in OL patients (OLP; n = 50) and NOHC (n = 25). (IV) Comparative distribution of OLN (n = 50), OLP (n = 50) and OHC (n = 19). (B) Bar graph showing mean of TL ratio in OL and HC groups. The bar graph represents the mean TL ratio in HC (total, n = 44; no habit, n = 25; with habit, n = 19), OLN (total, n = 50; no habit, n = 3; with habit, n = 47) and OLP (total, n = 50; no habit, n = 3; with habit, n = 47). Color code: yellow, green and red colors represent total, no habit and with habit, respectively, as indicated. Error bar indicates standard deviation. Significance of mean difference (t‐test) P < 0.5 is considered statistically significant; *P indicates significant when compared with all groups of healthy controls (total, no habit, habit) and **P indicates significant when compared with total and no‐habit healthy control.
Mean telomere length ratio in healthy control group in relation to oral high‐risk habits. TL, telomere length; HC, healthy control; Habit, oral high‐risk habit; No habit, no oral high‐risk habit; n, number of subjects.
| HC |
| TL ratio in oral tissue of HC |
Correlation with Age vs. TL ratio R ( | |
|---|---|---|---|---|
| Mean ± SD |
| |||
| Total | 44 | 1.18 ± 0.36 | ‐ | –0.069 (0.747) |
| No habit | 25 | 1.25 ± 0.30 | ‐ | |
| Habit | 19 | 1.09 ± 0.41 | 0.14 | 0.210 (0.388) |
| Smoking | 6 | 1.23 ± 0.51 | 0.88 | |
| Chewing raw tobacco (khaini) | 7 | 0.93 ± 0.38 | 0.02* | |
| Chewing gutkha | 10 | 1.27 ± 0.41 | 0.89 | |
| Drinking alcohol | 9 | 1.18 ± 0.46 | 0.59 | |
*P, P‐value is significant at the significance level P ≤ 0.05; R: the r statistic (measure of Pearson correlation).
Telomere length ratio in OL patient subgroups. TL, telomere length; Habit, oral high‐risk habit; No habit, no oral high‐risk habit; OLN, paired distal normal mucosa in OL patients; OLP, oral patch in OL patients; n, number of subjects.
| OL patients |
| TL ratio OL | |||
|---|---|---|---|---|---|
| OLN | OLP | ||||
| Mean ± SD |
| Mean ± SD |
| ||
| Habit/no habit | (vs no habit HC) | (vs no habit HC) | |||
| Total | 50 | 0.90 ± 0.28 | < 0.0001* | 0.97 ± 0.32 | 0.0005* |
| Habit | 47 | 0.90 ± 0.29 | < 0.0001* | 0.99 ± 0.32 | 0.0012* |
| Smoking | 18 | 0.99 ± 0.35 | 0.0110* | 1.00 ± 0.40 | 0.0217* |
| Chewing raw tobacco (Khaini) | 21 | 0.91 ± 0.26 | 0.0002* | 0.93 ± 0.32 | 0.0009* |
| Chewing gutkha | 26 | 0.93 ± 0.27 | 0.0002* | 1.01 ± 0.32 | 0.0071* |
| Drinking alcohol | 20 | 0.96 ± 0.27 | 0.0013* | 1.01 ± 0.320. | 0.0115* |
| No habit | 3 | 0.81 ± 0.08 | 0.018* | 0.73 ± 0.23 | 0.0071* |
| Clinical high/low risk | (High vs low risk) | (High vs low risk) | |||
| Homogeneous | 35 | 0.91 ± 0.30 | 0.596 | 0.99 ± 0.34 | 0.467 |
| Nonhomogeneous | 15 | 0.86 ± 0.26 | 0.92 ± 0.26 | ||
| Pathological high/low risk | (High vs low risk) | (High vs low risk) | |||
| No dysplasia | 46 | 0.92 ± 0.28 | 0.046* | 0.98 ± 0.33 | 0.404 |
| Dysplasia/carcinoma | 4 | 0.63 ± 0.06 | 0.84 ± 0.13 | ||
| Clinico‐pathological high/low risk (combined) | (High vs low risk) | (High vs low risk) | |||
| Homogeneous without dysplasia | 32 | 0.94 ± 0.30 | 0.208 | 1.01 ± 0.35 | 0.291 |
| Nonhomogeneous and or dysplasia | 18 | 0.82 ± 0.25 | 0.91 ± 0.25 | ||
*P, P‐value is significant at the significance level P ≤ 0.05.
Clinicopathological association with the telomere length ratio‐based subgrouping of OL. N, OLN; P, OLP; G, Number in the corresponding group of OL (A/B/C/D); NH, nonhomogeneous OL; n, number of nonhomogeneous OL or dysplasia cases as indicated.
| OL Group: (normal/small TL ratio in paired N and P) | % of total OL (50): % (G) | NH: % of G( | Dysplasia/carcinoma: % of G ( | Clinicopathological high‐risk OL (NH+Dysplasia/carcinoma) % of G( | ||
|---|---|---|---|---|---|---|
| A (N:normal, P:small) | 10 (5) | 20 (1) | 0 (0) |
(B + C):59 (10)
RR:2.42 (95%CI:1.18‐5.00, | ||
| B (N:small, P:normal) | 20 (10) | 30 (3) | (B + C): 41 (7) | 30 (3) | (B + C): 24 (4) | |
| C (N:small, P:small) | 14 (7) | 57 (4) | 14 (1) | (A + D): 24(8) | ||
| D (N:normal, P:normal) | 56 (28) | 25 (7) | 0 (0) | |||
| Total | 100 (50) | |||||
*P, P‐value is significant at the significance level P ≤ 0.05 (P‐values determined by Fisher exact probability due to small sample size); RR: relative risk.